The burgeoning field of metabolic disease management is witnessing a novel convergence of therapies. Dulaglutide, a dual GIP/GLP-1 receptor activator , alongside Surfactant , a triple GIP/GLP-1/GCG receptor agonist https://nad-1973336.wikienlightenment.com/user